SUBMIT MEDICAL INFORMATION REQUEST
Can’t find the information you are looking for? Would you like a copy of the full-text publication?
This site is intended for US Healthcare Professionals only
Publications
Urology & Uro-Oncology
Filters
Safety of nadofaragene firadenovec-vncg: review of data from phase 2 and phase 3 studies
Badrinath R. Konety, Yair Lotan, Amanda Myers
2025
Canadian Journal of Urology
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer, a study with 5-year follow-up: a plain language summary
Betty Wanga, Christopher Weighta, Adam Calawayb, et al.
2025
Future Oncology
Use of Nadofaragene Firadenovec-vncg: A Practical Guide for Nurses
Jennifer Sutton, RN, BS, CCRC; Toral Patel, RN, MN; and Caroline Branch, NP-C
2025
Urologic Nursing
Practical use of nadofaragene firadenovec-vncg for pharmacists
Seth D Holler and Sara Moran Smith
2025
Journal of Oncology Pharmacy Practice
Clinical use of nadofaragene firadenovec-vncg
Konety BR, Shore ND, Sant G
2024
Therapeutic Advances in Urology
Early experience using intravesical gene therapy for NMIBC: perspectives from urinary oncologists
Mmeje C, Mashni J.
2024
Pharm Times
Mechanism of action of nadofaragene firadenovec-vncg
Narayan V, Meeks JJ, Jakobsen JS, et al.
2024
Front Oncol
Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial
Narayan VM, Boorjian SA, Alemozaffar M, et al.
2024
Journal of Urology
Antiadenovirus antibodies predict response durability to nadofaragene firadenovec therapy in BCG-unresponsive non-muscle-invasive bladder cancer: secondary ...
Mitra AP, Narayan VM, Mokkapati S, et al.
2022
Eur Urol
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: A single-arm, open-label, repeat-dose clinical ...
Boorjian SA, Alemozaffar M, Konety BR, et al.
2021
Lancet Oncol
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Grabbert M, Seiler R, Gratzke C.
2021
Eur Urol
Patients and physician satisfaction of degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands
Roshani H, Roos E, Elzevier H, et al.
2021
Curr Urol
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical ...
Soria F, Gontero P.
2021
Eur Urol
Achieving clinically meaningful quality of life benefits in nocturia takes time: Results from a long-term, multicenter phase 3 study of desmopressin in ...
Juul K, Andersson F, Yamaguchi O.
2020
Low Urin Tract Symptoms
Neoadjuvant degarelix versus triptorelin in premenopausal patients who receive letrozole for locally advanced endocrine-responsive breast cancer ...
Dellapasqua S, Gray K, Munzone E, et al.
2019
J Clin Oncol
A practical approach to the management of nocturia
Oelke M, De Wachter S, Drake M, et al.
2017
Int J Clin Pract
Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer
Klotz L.
2015
Expert Opin Drug Metab Toxicol
Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix
Crawford E, Shore N, Moul J, et al.
2014
Urology
Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising ...
Klotz L, Miller K, Crawford E, et al.
2014
Eur Urol
Treatment of nocturia in women: Results of a randomized, controlled, double-blind, 3-month, phase III, safety and efficacy study of desmopressin orally...
Dmochowski R, Sand P, Van Der Meulen E, et al.
2013
J Urol
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
Klotz L, Boccon-Gibod L, Shore N, et al.
2008
BJU Int
Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study ...
Poppel H, Tombal B, Rosette J, et al.
2008
Eur Urol
Explore More
CONGRESSES
What congress material is available for this therapy area?